IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33036-y.html
   My bibliography  Save this article

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial

Author

Listed:
  • Daniel Mrak

    (Medical University of Vienna)

  • Daniela Sieghart

    (Medical University of Vienna)

  • Elisabeth Simader

    (Medical University of Vienna)

  • Selma Tobudic

    (Medical University of Vienna)

  • Helga Radner

    (Medical University of Vienna)

  • Peter Mandl

    (Medical University of Vienna)

  • Lisa Göschl

    (Medical University of Vienna)

  • Maximilian Koblischke

    (Medical University of Vienna)

  • Nikolaus Hommer

    (Medical University of Vienna)

  • Angelika Wagner

    (Medical University Vienna)

  • Margareta Mayer

    (Medical University of Vienna)

  • Lorenz Schubert

    (Medical University of Vienna)

  • Lukas Hartl

    (Medical University of Vienna)

  • Karin Kozbial

    (Medical University of Vienna)

  • Philipp Hofer

    (Medical University of Vienna)

  • Felix Kartnig

    (Medical University of Vienna)

  • Thomas Hummel

    (Medical University of Vienna)

  • Andreas Kerschbaumer

    (Medical University of Vienna)

  • Thomas Deimel

    (Medical University of Vienna)

  • Antonia Puchner

    (Medical University of Vienna)

  • Venugopal Gudipati

    (Medical University of Vienna)

  • Renate Thalhammer

    (Medical University of Vienna)

  • Petra Munda

    (Medical University of Vienna)

  • Keziban Uyanik-Ünal

    (Medical University of Vienna)

  • Andreas Zuckermann

    (Medical University of Vienna)

  • Gottfried Novacek

    (Medical University of Vienna)

  • Thomas Reiberger

    (Medical University of Vienna)

  • Erika Garner-Spitzer

    (Medical University Vienna)

  • Roman Reindl-Schwaighofer

    (Medical University of Vienna)

  • Renate Kain

    (Medical University of Vienna)

  • Stefan Winkler

    (Medical University of Vienna)

  • Josef S. Smolen

    (Medical University of Vienna)

  • Karin Stiasny

    (Medical University of Vienna)

  • Gottfried F. Fischer

    (Medical University of Vienna)

  • Thomas Perkmann

    (Medical University of Vienna)

  • Helmuth Haslacher

    (Medical University of Vienna)

  • Markus Zeitlinger

    (Medical University of Vienna)

  • Ursula Wiedermann

    (Medical University Vienna)

  • Judith H. Aberle

    (Medical University of Vienna)

  • Daniel Aletaha

    (Medical University of Vienna)

  • Leonhard X. Heinz

    (Medical University of Vienna)

  • Michael Bonelli

    (Medical University of Vienna)

Abstract

Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best vaccination strategy for this vulnerable group we performed a single center, 1:1 randomized blinded clinical trial. Patients who failed to seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) are randomized to receive either a third dose of the same mRNA or the vector vaccine ChAdOx1 nCoV-19. Primary endpoint is the difference in SARS-CoV-2 spike antibody seroconversion rate between vector and mRNA vaccinated patients four weeks after the third dose. Secondary outcomes include cellular immune responses. Seroconversion rates at week four are significantly higher in the mRNA (homologous vaccination, 15/24, 63%) as compared to the vector vaccine group (heterologous vaccination, 4/22, 18%). SARS-CoV-2-specific T-cell responses are reduced but could be increased after a third dose of either vector or mRNA vaccine. In a multivariable logistic regression analysis, patient age and vaccine type are associated with seroconversion. No serious adverse event is attributed to COVID-19 booster vaccination. Efficacy and safety data underline the importance of a booster vaccination and support the use of a homologous mRNA booster vaccination in immunosuppressed patients. Trial registration: EudraCT No.: 2021-002693-10.

Suggested Citation

  • Daniel Mrak & Daniela Sieghart & Elisabeth Simader & Selma Tobudic & Helga Radner & Peter Mandl & Lisa Göschl & Maximilian Koblischke & Nikolaus Hommer & Angelika Wagner & Margareta Mayer & Lorenz Sch, 2022. "Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33036-y
    DOI: 10.1038/s41467-022-33036-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33036-y
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-33036-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Roanne Keeton & Marius B. Tincho & Amkele Ngomti & Richard Baguma & Ntombi Benede & Akiko Suzuki & Khadija Khan & Sandile Cele & Mallory Bernstein & Farina Karim & Sharon V. Madzorera & Thandeka Moyo-, 2022. "T cell responses to SARS-CoV-2 spike cross-recognize Omicron," Nature, Nature, vol. 603(7901), pages 488-492, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hassen Kared & Asia-Sophia Wolf & Amin Alirezaylavasani & Anthony Ravussin & Guri Solum & Trung The Tran & Fridtjof Lund-Johansen & John Torgils Vaage & Lise Sofie Nissen-Meyer & Unni C. Nygaard & Ola, 2022. "Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    2. Fanglei Zuo & Hassan Abolhassani & Likun Du & Antonio Piralla & Federico Bertoglio & Leire Campos-Mata & Hui Wan & Maren Schubert & Irene Cassaniti & Yating Wang & Josè Camilla Sammartino & Rui Sun & , 2022. "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    3. Jaime S. Rosa Duque & Xiwei Wang & Daniel Leung & Samuel M. S. Cheng & Carolyn A. Cohen & Xiaofeng Mu & Asmaa Hachim & Yanmei Zhang & Sau Man Chan & Sara Chaothai & Kelvin K. H. Kwan & Karl C. K. Chan, 2022. "Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    4. Chihiro Motozono & Mako Toyoda & Toong Seng Tan & Hiroshi Hamana & Yoshihiko Goto & Yoshiki Aritsu & Yusuke Miyashita & Hiroyuki Oshiumi & Kimitoshi Nakamura & Seiji Okada & Keiko Udaka & Mizuki Kitam, 2022. "The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    5. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    6. Yuexiu Zhang & Michelle Chamblee & Jiayu Xu & Panke Qu & Mohamed M. Shamseldin & Sung J. Yoo & Jack Misny & Ilada Thongpan & Mahesh KC & Jesse M. Hall & Yash A. Gupta & John P. Evans & Mijia Lu & Chen, 2024. "Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    7. Shaofeng Deng & Ying Liu & Rachel Chun-Yee Tam & Pin Chen & Anna Jinxia Zhang & Bobo Wing-Yee Mok & Teng Long & Anja Kukic & Runhong Zhou & Haoran Xu & Wenjun Song & Jasper Fuk-Woo Chan & Kelvin Kai-W, 2023. "An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    8. Annika Rössler & Antonia Netzl & Ludwig Knabl & Helena Schäfer & Samuel H. Wilks & David Bante & Barbara Falkensammer & Wegene Borena & Dorothee Laer & Derek J. Smith & Janine Kimpel, 2022. "BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    9. Khadija Khan & Gila Lustig & Cornelius Römer & Kajal Reedoy & Zesuliwe Jule & Farina Karim & Yashica Ganga & Mallory Bernstein & Zainab Baig & Laurelle Jackson & Boitshoko Mahlangu & Anele Mnguni & Ay, 2023. "Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    10. Rúbens Prince dos Santos Alves & Julia Timis & Robyn Miller & Kristen Valentine & Paolla Beatriz Almeida Pinto & Andrew Gonzalez & Jose Angel Regla-Nava & Erin Maule & Michael N. Nguyen & Norazizah Sh, 2024. "Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    11. Hung Fu Tseng & Bradley K. Ackerson & Lina S. Sy & Julia E. Tubert & Yi Luo & Sijia Qiu & Gina S. Lee & Katia J. Bruxvoort & Jennifer H. Ku & Ana Florea & Harpreet S. Takhar & Radha Bathala & Cindy Ke, 2023. "mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    12. Matthias Reinscheid & Hendrik Luxenburger & Vivien Karl & Anne Graeser & Sebastian Giese & Kevin Ciminski & David B. Reeg & Valerie Oberhardt & Natascha Roehlen & Julia Lang-Meli & Kathrin Heim & Nina, 2022. "COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    13. Daan K. J. Pieren & Sebastián G. Kuguel & Joel Rosado & Alba G. Robles & Joan Rey-Cano & Cristina Mancebo & Juliana Esperalba & Vicenç Falcó & María J. Buzón & Meritxell Genescà, 2023. "Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    14. Farina Karim & Catherine Riou & Mallory Bernstein & Zesuliwe Jule & Gila Lustig & Strauss Graan & Roanne S. Keeton & Janine-Lee Upton & Yashica Ganga & Khadija Khan & Kajal Reedoy & Matilda Mazibuko &, 2024. "Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    15. Martin J. Scurr & George Lippiatt & Lorenzo Capitani & Kirsten Bentley & Sarah N. Lauder & Kathryn Smart & Michelle S. Somerville & Tara Rees & Richard J. Stanton & Awen Gallimore & James P. Hindley &, 2022. "Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    16. Julia T. Castro & Patrick Azevedo & Marcílio J. Fumagalli & Natalia S. Hojo-Souza & Natalia Salazar & Gregório G. Almeida & Livia I. Oliveira & Lídia Faustino & Lis R. Antonelli & Tomas G. Marçal & Ma, 2022. "Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    17. Georg M. N. Behrens & Joana Barros-Martins & Anne Cossmann & Gema Morillas Ramos & Metodi V. Stankov & Ivan Odak & Alexandra Dopfer-Jablonka & Laura Hetzel & Miriam Köhler & Gwendolyn Patzer & Christo, 2022. "BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    18. Nicole Wolter & Waasila Jassat & Sibongile Walaza & Richard Welch & Harry Moultrie & Michelle J. Groome & Daniel Gyamfi Amoako & Josie Everatt & Jinal N. Bhiman & Cathrine Scheepers & Naume Tebeila & , 2022. "Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa," Nature Communications, Nature, vol. 13(1), pages 1-8, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33036-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.